Regression of a venous malformation during angiotensin-converting enzyme inhibitor treatment for hypertension

Recent studies have reported that components of the renin-angiotensin system (RAS) are expressed in venous malformations by embryonic stem cell-like subpopulations. It has been hypothesized that these cells are sustained by the RAS and, therefore, could be a novel therapeutic target, using medicatio...

Full description

Saved in:
Bibliographic Details
Published in:Journal of vascular surgery cases and innovative techniques 2022-12, Vol.8 (4), p.657-659
Main Authors: Berger, Sigurd, Bjark, Therese Halvorsen, Midtvedt, Karsten, Andersen, Rune
Format: Article
Language:English
Subjects:
Case report
Therapeutics
Vascular malformations
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent studies have reported that components of the renin-angiotensin system (RAS) are expressed in venous malformations by embryonic stem cell-like subpopulations. It has been hypothesized that these cells are sustained by the RAS and, therefore, could be a novel therapeutic target, using medications such as angiotensin-converting enzyme inhibitors. A young man with a symptomatic intramuscular venous malformation of the upper limb, and hypertension was treated with an angiotensin-converting enzyme inhibitor. After 8 months of treatment, we registered a considerable volume reduction of the venous malformation and a reduction in pain. Our observation warrants further research on the link between the RAS and venous malformations.
ISSN:2468-4287
2468-4287
DOI:10.1016/j.jvscit.2022.09.004